Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Vitamin K Epoxide Reductase Complex Subunit 1"'
Autor:
E. S. Levitskaya, A. A. Kastanayan, G. N. Leonova, A. A. Yakovlev, S. A. Zatonsky, L. A. Ganenko
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 1 (2023)
Anticoagulants are widely used in clinical practice to reduce the risk of cardiovascular events. However, there are associated clinical conditions that require coagulation system monitoring due to an increased risk of bleeding. In clinical practice,
Externí odkaz:
https://doaj.org/article/bb60129bc1a543d8bdf2a6874ebb19ef
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Burassakorn Subsuphan, Chatchai Chinpaisal, Manat Pongchaidecha, Wibun Phanthabordeekorn, Surawut Watana
Publikováno v:
Archives of Pharmacy Practice, Vol 7, Iss 1, Pp 18-25 (2016)
Aims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)FNx013 and Vitamin K epoxide reductase complex subunit 1-1639 (VKORC1-1639) G >A and patient′s characteristics on warfarin do
Externí odkaz:
https://doaj.org/article/6c688fdb7f764cdaadf739eba24e113c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Pest Science. 94:805-815
Resistance to anticoagulant rodenticides in Norway rats has been primarily explained by selection on the mutations in the vitamin K epoxide reductase complex subunit 1 (Vkorc1) gene. Whether warfarin resistance can be induced independent of Vkorc1 mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f07ad86e3982e7699bb1fae3918833e
https://doi.org/10.1007/s10340-020-01299-3
https://doi.org/10.1007/s10340-020-01299-3
Autor:
Cornelius F.H. Mueller, Marc Ulrich Becher, Adem Aksoy, E Repges, Vedat Tiyerili, Sebastian Zimmer, M Al Zaidi, Georg Nickenig, Johannes Oldenburg
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine
Background Vitamin K antagonists (VKA) like Warfarin are known to promote adverse cardiovascular remodelling. Contrarily, vitamin K supplementation has been discussed to decelerate cardiovascular disease. The recently described VKOR-isoenzyme Vitamin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81389b662158a6a2ed8b2b30ed4fb873
https://www.frontiersin.org/articles/10.3389/fcvm.2021.708946/full
https://www.frontiersin.org/articles/10.3389/fcvm.2021.708946/full
Autor:
Shinichiro Minami, Hironobu Yagishita, Yumiko Akamine, Masatomo Miura, Katsunori Iijima, Shotaro Kato
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 44:977-980
What is known and objective Lenvatinib inhibits CYP2C8. (S)-Warfarin is metabolized to (S)-7-hydroxywarfarin by CYP2C9 and (S)-4'-hydroxywarfarin by CYP2C8. Here, we report drug interactions between warfarin and lenvatinib in a patient with CYP2C9*1/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9721273c599960a917f83832877fe2b
https://doi.org/10.1111/jcpt.13030
https://doi.org/10.1111/jcpt.13030
Autor:
Jacob Kames, Anton A. Komar, Michael DiCuccio, Ryan C. Hunt, Nobuko Hamasaki-Katagiri, Chava Kimchi-Sarfaty, Aikaterini Alexaki, Kyle Laurie, Nancy E. Hernandez, David D. Holcomb
Publikováno v:
PLoS Computational Biology, Vol 17, Iss 3, p e1008805 (2021)
PLoS Computational Biology
PLoS Computational Biology
Thrombosis is a recognized complication of Coronavirus disease of 2019 (COVID-19) and is often associated with poor prognosis. There is a well-recognized link between coagulation and inflammation, however, the extent of thrombotic events associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9c77a6c134f7a3b86ee3a5ecd12b29
https://doaj.org/article/518b9cb3c9e9405bb80b8b976a90bf35
https://doaj.org/article/518b9cb3c9e9405bb80b8b976a90bf35
Autor:
Xiao-Yang Zhou, Xiang-Ran Lu, Ying-Hui Li, Ya-Qing Ma, Shi-Wen Zhao, Fang Wang, Ren-Ai Xu, Guo-Xin Hu, Jian-Ping Cai
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Warfarin is a widely prescribed anticoagulant but the doses required to attain the optimum therapeutic effect exhibit dramatic inter-individual variability. Pharmacogenomics-guided warfarin dosing has been recommended to improve safety and effectiven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e719312ab25de9ee83feb9d82cbe50
https://www.frontiersin.org/articles/10.3389/fphar.2021.619339/full
https://www.frontiersin.org/articles/10.3389/fphar.2021.619339/full